The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Open accessAbstract
CONTEXT: Glucagon-like peptide-1 (GLP-1) 7-36 amide, an insulinotropic hormone released from the intestinal L cells in response to nutrient ingestion, has been extensively reviewed with respect to beta-cell function. However GLP-1 receptors are abundant in many other tissues. Thus, the function of GLP-1 is not limited to the islet cells, and it has regulatory actions on many other organs. EVIDENCE ACQUISITION: A review of published, peer-reviewed medical literature (1987 to September 2008) on the extrapancreatic actions of GLP-1 was performed. EVIDENCE SYNTHESIS: The extrapancreatic actions of GLP-1 include inhibition of gastric emptying and gastric acid secretion, thereby fulfilling the definition of GLP-1 as an enterogastrone. Other important extrapancreatic actions of GLP-1 include a regulatory role in hepatic glucose production, the inhibition of pancreatic exocrine secretion, cardioprotective and cardiotropic effects, the regulation of appetite and satiety, and stimulation of afferent sensory nerves. The primary metabolite of GLP-1, GLP-1 (9-36) amide, or GLP-1m, is the truncated product of degradation by dipeptidyl peptidase-4. GLP-1m has insulinomimetic effects on hepatic glucose production and cardiac function. Exendin-4 present in the salivary gland of the reptile, Gila monster (Heloderma suspectum), is a high-affinity agonist for the mammalian GLP-1 receptor. It is resistant to degradation by dipeptidyl peptidase-4, and therefore has a prolonged half-life. CONCLUSION: GLP-1 and its metabolite have important extrapancreatic effects particularly with regard to the cardiovascular system and insulinomimetic effects with respect to glucose homeostasis. These effects may be particularly important in the obese state. GLP-1, GLP-1m, and exendin-4 therefore have potential therapeutic roles because of their diffuse extrapancreatic actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 1×
“Egan and colleagues (106) have shown that human duodenal L cells and taste cells of the tongue express the sweet taste receptor G protein gustducin, which is probably involved in the regulation of GLP-1 release.”
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 8×
“Glucagon-like peptide-1 (7-36) amide (GLP-1) is a 29-amino acid hormone secreted from the L cells of the small intes-”
InfluentialSelf-citationDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 8×
“Glucagon-like peptide-1 (7-36) amide (GLP-1) is a 29-amino acid hormone secreted from the L cells of the small intes-”
InfluentialSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Self-citationGlucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649 · cited 1×
“(2) in hamster and man, the presence of”
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · cited 7×
“Half of the volunteers underwent a third clamp in which the known GLP-1R was blocked with the infusion of the GLP-1 (7-36) antagonist, exendin (9-39) amide, starting 60 min before infusion of GLP-1m.”
InfluentialGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Buteau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 7×
“Half of the volunteers underwent a third clamp in which the known GLP-1R was blocked with the infusion of the GLP-1 (7-36) antagonist, exendin (9-39) amide, starting 60 min before infusion of GLP-1m.”
InfluentialMeeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303 · cited 1×
“The solid circles represent animals given 3 nmol GLP-1, and open circles represent control animals that received saline (100).”
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · cited 2×
“putative GLP-1m receptor may be present in cardiac tissue (77).”
Self-citationDelgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235 · cited 1×
“It should be noted that the effect of delayed gastric emptying has been generally demonstrated with physiological or supraphysiological exogenously administered GLP-1 (56, 57).”
Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity
Elahi, D., Nagulesparan, M., Hershcopf, R. J., Muller, D. C., Tobin, J. D., Blix, P. M., Rubenstein, A. H., Unger, R. H., & Andres, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198205203062002 · Cited by 210 · cited 1×
“An example of this is the documented suppression of C-peptide levels when insulin is infused (61).”
Self-citationGlucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188 · cited 1×
“Previous studies showed that GLP-1 was able to relax the femoral artery tone in a dose-response manner in rats (116) and that it is associated with vasodilatation induced by”
HEINRICH, G., GROS, P., LUND, P. K., BENTLEY, R. C., & HABENER, J. F. (1984) · Endocrinology · doi:10.1210/endo-115-6-2176 · Cited by 158
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Barragán, J. M., Eng, J., Rodríguez, R., & Blázquez, E. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.5.e784 · Cited by 142 · cited 2×
“The agonists of GLP-1R have been shown to have vascular and cardiac actions in humans as well as in rodents; these actions include the effects on cardiac output, blood pressure, contractility (65, 66, 68, 73), and cardioprotection (34, 67, 70, 74).”
Nikolaidis, L. A., Doverspike, A., Hentosz, T., Zourelias, L., Shen, Y.-T., Elahi, D., & Shannon, R. P. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073890 · Cited by 137 · cited 2×
“The agonists of GLP-1R have been shown to have vascular and cardiac actions in humans as well as in rodents; these actions include the effects on cardiac output, blood pressure, contractility (65, 66, 68, 73), and cardioprotection (34, 67, 70, 74).”
Self-citationBeak, S. A., Heath, M. M., Small, C. J., Morgan, D. G., Ghatei, M. A., Taylor, A. D., Buckingham, J. C., Bloom, S. R., & Smith, D. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci610 · Cited by 133
Green, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382774 · Cited by 111 · cited 8×
“Glucagon-like peptide-1 (7-36) amide (GLP-1) is a 29-amino acid hormone secreted from the L cells of the small intes-”
InfluentialSalehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108
Cited by
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2017) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 410
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Metadata
- Authors
- Abu-Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., Andersen, D. K., & Elahi, D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-06-01
- Volume
- 94
- Issue
- 6
- Pages
- 1843-1852
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2090898804
- Cited by
- 200
- References
- 36
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.